(NASDAQ: MLTX) Moonlake Immunotherapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 63.49%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 6.64%.
Moonlake Immunotherapeutics's revenue in 2023 is $0.On average, 3 Wall Street analysts forecast MLTX's revenue for 2027 to be $5,644,494,392, with the lowest MLTX revenue forecast at $5,133,061,611, and the highest MLTX revenue forecast at $6,024,166,102. On average, 3 Wall Street analysts forecast MLTX's revenue for 2028 to be $34,649,414,794, with the lowest MLTX revenue forecast at $17,266,320,383, and the highest MLTX revenue forecast at $44,405,354,156.
In 2029, MLTX is forecast to generate $84,000,492,546 in revenue, with the lowest revenue forecast at $37,417,646,196 and the highest revenue forecast at $121,014,737,550.